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both tests being performed with an adequate power and control of the 
overall false positive error. When the rate of sensitive patients is low, 
this design reduces the chance of false rejection of an effective treat-
ment by the detection of an effect on a patients subgroup and when this 
rate is high, it does not affect much the probability of detecting the true 
overall effect.
Targeted designs are designs for whom the patients populations are en-
riched by a further selection criterion related to a marker. This marker, 
when positive, is supposed to be predictive for response to an inves-
tigational treatment and only patients with a positive marker will be 
eligible for a trial and those patients can be classically randomized be-
tween a control arm and the investigational, targeted for the presence of 
the marker, treatment. To be practically feasible, such a design requires 
that a reproducible method for assessing the marker does exist and can 
be applied quickly before randomizing a patient. Simon and Maito-
urnam (3) evaluated the efﬁciency of this design in terms of the gain 
of patients to be randomised and in terms of the gain of patients to be 
screened, according to various parameters : the proportion of sensitive 
patients and the accuracy of the method to select them, the response to 
the control arm, the differential effect of the investigational treatment in 
sensitive patients and in non sensitive patients compared to the control 
arm, the absolute improvement with the investigational treatment in 
sensitive patients. They showed that the reduction in the number of 
patients to be randomised can be very substantial in particular when the 
investigational treatment does not bring any beneﬁt for non sensitive 
patients, when there is an accurate method for identifying the sensitive 
patients (falsely identiﬁed sensitive patients will dilute treatment effect 
while falsely identiﬁed non sensitive patients will imply a higher num-
ber of patients to screen) and when the proportion of sensitive patients 
is low. In the situation, when there is no beneﬁt of the investigational 
treatment for non sensitive patients, the targeted design is also more 
efﬁcient than the untargeted design with regard to the required number 
of patients to screen.
A design where all patients are randomised, regardless of the positivity 
of the marker, can also be considered with a prospective assessment of 
that marker and a separate randomization procedure for sensitive and 
non sensitive patients. At the end of the trial, separate analyses can be 
conducted for the two subgroups or an interaction effect between treat-
ment and the sensitivity status may be looked at. Sample sizes required 
will depend on the type of analysis chosen (as well as on the proportion 
of sensitive patients and on the differential hypotheses formulated in 
the two strata) (4).
Other designs consider a strategy based on the sensitivity status (4). 
Once the status is known, patients are randomized to a strategy based 
on the marker of sensitivity or not based on the marker. One possibil-
ity is, in the strategy based on the sensitivity status, to treat with the 
investigational treatment patients expected to be sensitive while giving 
the control arm to the other patients. In the strategy not based on the 
marker, the control treatment is administered to all patients. This design 
however does not allow the assessment of the investigational treatment 
in the expected non sensitive patients as in one arm none of the patients 
receives the investigational treatment. It can then be modiﬁed to further 
randomize the patients allocated to the strategy not based on the marker 
between the control arm and the targeted therapy.
While in randomized phase III clinical trials, primary endpoint remains 
overall survival (or disease-free survival in some circumstances), 
the development of biological agents which may be cytostatic rather 
than cytotoxic may raise issues regarding the choice of the endpoint 
in phase II clinical trials, being classically response to treatment to 
take into account that the expected effect will rather be to slow or to 
stop the growth of the tumors rather than shrinking the lesions. More 
adequate endpoints may be stabilization rate or the rate of patients 
without progression at a particular time point (5). When these primary 
endpoints are considered, investigators may be faced with a lack of 
historical controls to formulate assumptions regarding acceptable and 
unacceptable rates of stabilisation or of patients without progression 
in addition to the problem that there might be no reliable assay for 
selecting patients susceptible to beneﬁt for the investigational treat-
ment. In such a situation, a design called randomized discontinuation 
design has been proposed by Rosner et al (6). All patients are initially 
given the drug. After a ﬁrst assessment, responding patients continue 
with the drug, treatment is stopped in progressing patients and patients 
with stabilisation are randomized between continuation with drug or 
continuation with a placebo with the expectation that the randomized 
patients population is a more homogeneous population of sensitive 
patients. The efﬁciency of this design has been studied by Freidlin and 
Simon (7) by comparing it to an upfront randomized design. They show 
that the degree of enrichment (ie the fraction of sensitive patients in the 
randomized part of the study) is the key factor for the success of the 
randomized discontinuation design.
Examples of trials having considered the described designs will be 
given in the context of the development of targeted agents for patients 
with lung cancer.
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Lung cancer is the most frequent cause of cancer deaths worldwide and 
its global incidence has been steadily increasing during recent decades. 
Surgery is the cornerstone of treatment in localized NSCLC but only 
20% of patients are considered surgical candidates at presentation. The 
vast majority of patients cannot be subjected to surgery either because 
of tumor advancement or poor medical condition. Patients with medi-
cally inoperable or locally advanced NSCLC are usually managed with 
radiotherapy, but only a few enjoy long-term survival. The limited 
efﬁcacy of single therapeutic modalities has led to the development of 
combination strategies, the subject of this presentation. 
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Combining surgery and chemotherapy
Treatment outcomes after pulmonary resection are modest, with ﬁve-
year survival rates ranging from 65% in stage I to less than 10% in 
stage IIIA. One of the approaches intended to improve the outcome is 
combining surgery with chemotherapy. This method includes the appli-
cation of chemotherapy prior to or after surgery (respectively: induction 
and adjuvant chemotherapy). The addition of chemotherapy to surgery 
has been believed to eliminate tumor foci outside the thorax. Preopera-
tive (induction) chemotherapy additionally aims at facilitating surgery 
or even in making it possible in some primarily inoperable patients. 
Induction chemotherapy has attracted attention after two small random-
ized studies had suggested considerable survival beneﬁt from this ap-
proach in patients with stage IIIA disease [1,2]. However, a subsequent 
large randomized study including also patients with stage IB and II 
disease, demonstrated a much smaller gain from this approach [3]. Al-
though the exact role of preoperative chemotherapy in NSCLC remains 
to be established, this method has been introduced in some institutions 
as a routine management in patients with locally extended disease (T3-
T4 or N2). More data on the usefulness of induction chemotherapy in 
NSCLC will emerge soon as a result of recently completed randomized 
studies. 
Although in operable NSCLC metastatic spread is the most common 
form of relapse, until recently the role of postoperative chemotherapy 
in this tumor was generally questioned. Major concerns included the 
modest activity, considerable toxicity and poor compliance of this treat-
ment [4]. A series of early small randomized studies provided contra-
dictory results and their metaanalysis, published in 1995, indicated only 
a trend toward improved ﬁve-year survival in patients applied cispla-
tin-based chemotherapy (absolute beneﬁt of 4%; p=0.08) [5]. More 
recently however, there has been increasing evidence from individual 
studies that adjuvant chemotherapy in NSCLC may provide a signiﬁ-
cant survival beneﬁt. The pooled analysis of the ﬁve recent large trials 
using platinum-based adjuvant therapy conﬁrmed the overall survival 
beneﬁt of this method, with the absolute mortality reduction of 4.2% at 
ﬁve years [6]. The beneﬁt varied with stage, with virtually no gain in 
stage I, and a hazard ratio of 0.83 in stages II and III. Currently, many 
centers consider adjuvant chemotherapy a standard management in 
selected NSCLC patients. The candidates for adjuvant chemotherapy 
include stage II or III patients with adequate postoperative recov-
ery, good performance status and the absence of clinically relevant 
comorbidity. Chemotherapy should preferably include 3-4 cycles of a 
two-drug cisplatin-based regimen. Recently, research has been focused 
on biological predictors which could more precisely identify candidates 
for adjuvant chemotherapy. 
Combining surgery and radiotherapy 
A series of randomized studies performed in the 1960s and early 1970s 
demonstrated that preoperative radiotherapy was able to sterilize tumor 
in the chest, but this was not translated into survival beneﬁt. Moreover, 
preoperative radiotherapy was associated with more frequent serious 
postoperative complications [7,8]. These studies were ﬂawed in their 
design and execution; nevertheless, it is unlikely that preoperative 
radiation may carry a substantial beneﬁt in NSCLC. Postoperative ra-
diotherapy has been believed to sterilize small deposits of lung cancer, 
thus leading to a reduction of locoregional relapse rate and prolonga-
tion of survival. A number of randomized studies, including in total 
more than 2000 patients, addressed the value of adding radiation to 
curative pulmonary resection. These studies varied in design, selec-
tion criteria and numbers of patients yet their results have in general 
been uniform. Despite the decreased rate of local recurrences, there 
was no survival beneﬁt with postoperative irradiation [7,8]. It should 
be remembered, however, that early randomized studies suffered from 
suboptimal radiation doses and obsolete techniques, inclusion of large 
proportions of ineligible patients, inappropriate staging and the lack 
of quality control programs. Given all these limitations, the impact of 
adjuvant radiotherapy on the clinical outcome of NSCLC still remains 
highly undetermined. 
Combining surgery with radiotherapy and chemotherapy
The approaches consisting of surgery, chemotherapy and radiation 
have been tested mainly in IIIA-N2 disease. A recent phase III study 
compared initial or concomitant chemoradiotherapy followed by either 
surgery or additional chemoradiotherapy [9]. Progression-free survival 
was longer in the surgery group but this effect was not translated into 
improved overall survival. Additionally, triple-modality therapy was 
associated with signiﬁcant toxicity. In another study, patients who re-
sponded to induction chemotherapy were randomized to surgical resec-
tion or radiotherapy [10]. In the surgery arm, 40% of patients received 
postoperative radiotherapy. Five-year overall survival in patients who 
did and did not undergo resection were virtually the same. The results 
of these two studies indicate that the role of surgery in stage IIIA-N2 
NSCLC is still questionable and further clinical research is warranted 
to develop an optimal strategy in this subset. 
Given the relatively high risk of distant relapse following surgery, a 
combination of radiotherapy and chemotherapy was tested in the adju-
vant setting. However, the randomized study comparing postoperative 
radiotherapy alone or with concurrent chemotherapy failed to identify 
any survival advantage of the triple approach [11].
Combining radiotherapy and chemotherapy
The major expectation from the addition of chemotherapy to radia-
tion is to increase survival by improving tumor control in the thorax 
and by eliminating the emergence of metastatic disease. The two most 
frequently investigated strategies of combined chemotherapy and 
radiation include primary chemotherapy followed by radiation, and 
concurrent chemoradiation. Primary chemotherapy principally aims 
at an eradication of micrometastatic disease and at a reduction of the 
volume of the primary tumor, whereas concomitant chemoradiation is 
expected to improve locoregional control by making tumor cells more 
vulnerable to radiotherapy (radiosensitization). The results of phase III 
trials comparing radiation alone with a combination of radiation and 
chemotherapy demonstrated modest but signiﬁcant survival beneﬁt 
from the latter [12]. In the positive studies using combined radiation 
and chemotherapy, primary chemotherapy seemed to reduce the rate of 
distant metastases, whereas the concomitant approach provided better 
local control of the tumor12. A series of recent studies suggested that 
concomitant chemoradiation is more effective than chemotherapy pre-
ceding radiation [13]. The gain from the concurrent use of both modali-
ties should, however, be weighed against increased acute toxicity. No 
further survival beneﬁt was demonstrated from combining sequential 
and concomitant chemoradiation over either strategy alone [14-17].
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Background
Malignant thoracic tumor is a disease with high incidence and mortal-
ity, and incidence is expected to continue to rise in future. Surgery is 
the ﬁrst choice of therapy, but is not indicated in many cases. While 
systemic chemo- and radiotherapy have been used for unresectable ma-
lignant thoracic tumors, satisfactory results are not usually obtained. A 
great need currently exists for the establishment of effective treatments 
for unresectable malignant thoracic tumors. Radiofrequency (RF) abla-
tion has been examined as an effective minimally invasive treatment 
for many neoplasms, including malignant liver tumors, and has been 
used in recent years to treat bone, kidney, adrenal gland, thyroid gland, 
breast and brain neoplasms. Several experimental studies have reported 
that RF ablation is highly effective, because lung tumors are surround-
ed by normal pulmonary parenchyma, resulting in the so-called “oven 
effect”. Ever since the study by Dupuy et al. [1], several studies have 
investigated short, middle, and long-term results for RF ablation in the 
treatment of lung tumors [2-4]. The present study retrospectively inves-
tigated mid-term technique effectiveness of malignant thoracic tumors 
after RF ablation in our institute. We focused on the relations between 
technical effectiveness and tumor size, and ground-glass attenuation 
(GGA) appears around a tumor during or immediately after RF abla-
tion. We also reviewed complications related to lung RF ablation.
Materials and Methods
Between June 2001 and March 2007, CT-guided RF ablation was per-
formed on 834 malignant lung tumors of 304 patients in our institute. 
In this presentation we reviewed our patients between June 2001 and 
January 2006. Patients for whom periodical follow-up CT was not 
performed after RF ablation were excluded from the present study. As a 
result, we retrospectively investigated 461 tumors in 169 patients (109 
men and 60 women) who underwent periodical follow-up CT after RF 
ablation.
Mean patient age at the time of ﬁrst RF ablation was 63.2 years (range, 
24-88 years). Tumors comprised primary lung cancer in 32 patients (34 
tumors), and lung metastases in 137 patients (427 tumors). Surgery was 
not indicated in any case ( unresectable due to other diseases, refusal to 
undergo surgery, or advanced cancer,). All primary lung tumors were 
non-small cell carcinomas. Metastatic disease was from colon cancer (n 
= 154), lung cancer (n = 76), renal cell carcinoma (n = 67), hepatocel-
lular carcinoma (n = 31), urachal cancer (n = 23), uterine leiomyosar-
coma (n = 19), adenoid cystic carcinoma (n = 15), esophageal cancer (n 
= 11), adrenal cancer (n = 10), synovial sarcoma (n = 9), ureteral cancer 
(n = 8) and others (n = 38).
In all cases, percutaneous RF ablation was performed under CT ﬂuo-
loscopy guidance while monitoring vital signs and continuous pulse 
oximetry. As a general rule, 0.1-0.3 mg of fentanyl citrate was used as 
an analgesic, and RF ablation was performed under local anesthesia 
using lidocaine . As necessary, epidural anesthesia was administered by 
percutaneously injecting 5-10 ml of 2% lidocaine and 1 ml of fentanyl 
through an epidural tube.
In 214 tumors, a Cool-tip electrode and a generator (CC-1; Radionics, 
Burlington, USA) were used. In 244 tumors, a LeVeen electrode and 
generator (RF2000/3000; Boston Scientiﬁc, Natic, USA) were used. 
With the Radionics RF ablation machine, cold physiological saline was 
circulated within the lumen of the puncture electrode, and RF ablation 
was performed for 12 min. Immediately after RF ablation, tempera-
ture of the electrode tip placed at the tumor was measured. Ablation 
was completed if temperature was ≥60 ˚C. If temperature was <60 ˚C, 
ablation was performed again. With the Boston Scientiﬁc RF ablation 
machine, ablation was performed until impedance drastically increased. 
As a general rule, each area was cauterized twice. If a tumor was too 
large to be ablated in a single session, the electrode was re-inserted as 
needed until ablation volume exceeded tumor volume as assessed on 
CT [20].
Follow-up CT study was conducted immediately after, 1-2 months, 4-6 
months and 9-12 months after RF ablation, then every 6 months there-
after. When not contraindicated, contrast-enhanced CT was performed 
at the same time.
When examined by CT, ground-glass attenuation (GGA) appears 
around a tumor during or immediately after RF ablation. Based on the 
notion that GGA is equivalent to heat-damaged pulmonary parenchyma 
including the tumor, each ablation was performed to maximize GGA 
until ablation volume exceeded tumor volume as assessed on CT. A 
review of CT ﬁndings showed that GGA varied widely. We classiﬁed 
them into complete or incomplete-type when we reviewed them.
Results
Technical success: A total of 253 sessions were performed on the 169 
patients to treat the 461 tumors. All sessions were completed without 
procedure-related severe complication or death.
Local progression: During the assessment period, local progression did 
not occur in 369 of the 461 tumors (80.0%). Overall 1-, 2- and 3-year 
primary technique effectiveness rates as assessed by Kaplan-Meier 
methods were 72.3%, 59.5% and 53.0%, respectively. On the other 
hand, local progression occurred in 92 tumors (20.0%) during the same 
period. Re-RF ablation was performed on 41 tumors (44.6%). Re-RF 
ablation was performed once on 35 tumors, twice on 5 tumors and three 
times on 1 tumor. During the assessment period, secondary technique 
effectiveness rate was 86.6% (399 of the 461 tumors). Overall 1-, 2- 
and 3-year secondary technique effectiveness rates were 82.1%, 70.5% 
and 63.8%, respectively.
In relation to tumor size, local progression did not occur during the 
assessment period in 300 of the 355 tumors ≤2 cm (84.5%), 39 of the 
63 tumors 2-3 cm (69.8%) and 30 of the 43 tumors >3 cm (69.8%). The 
1-, 2- and 3-year technique effectiveness rates for each tumor size as 
determined by Kaplan-Meier methods were as follows: ≤2 cm tumors, 
78.4%, 65.6% and 57.6%, respectively; 2-3 cm tumors, 50.0%, 33.7% 
and not assessed (because of small number) , respectively; and >3 cm 
tumors, 53.1%, 44.3% and not assessed (because of small number), 
respectively. 
